

# Usefulness of the second heart sound for predicting pulmonary hypertension in patients with interstitial lung disease

Utilidade da segunda bulha cardíaca na predição de hipertensão pulmonar em portadores de doenças intersticiais pulmonares

Sandra de Barros Cobra<sup>1</sup>, Rayane Marques Cardoso<sup>II</sup>, Marcelo Palmeira Rodrigues<sup>III</sup>

Universidade de Brasília (UnB), Brasília, Distrito Federal, Brazil

<sup>I</sup>MD, MSc. Cardiologist, Hospital de Base do Distrito Federal (HBDF), Brasília, Federal District, Brazil.

<sup>II</sup>MD. Resident in General Surgery, Universidade de Brasília (UnB), Brasília, Federal District, Brazil.

<sup>III</sup>MD, MSc, PhD. Professor, School of Medicine, Universidade de Brasília (UnB), Brasília, Federal District, Brazil.

## KEYWORDS:

Hypertension, pulmonary.  
Lung diseases, interstitial.  
Heart auscultation.  
Echocardiography.  
Phonocardiography.

## PALAVRAS-CHAVE:

Hipertensão pulmonar.  
Doenças pulmonares intersticiais.  
Auscultação cardíaca.  
Ecocardiografia.  
Fonocardiografia.

## ABSTRACT

**CONTEXT AND OBJECTIVE:**  $P_2$  hyperphoresis is considered to be a valuable finding in semiological diagnoses of pulmonary hypertension (PH). The aim here was to evaluate the accuracy of the pulmonary component of second heart sounds for predicting PH in patients with interstitial lung disease.

**DESIGN AND SETTING:** Cross-sectional study at the University of Brasilia and Hospital de Base do Distrito Federal. **METHODS:** Heart sounds were acquired using an electronic stethoscope and were analyzed using phonocardiography. Clinical signs suggestive of PH, such as second heart sound ( $S_2$ ) in pulmonary area louder than in aortic area;  $P_2 > A_2$  in pulmonary area and  $P_2$  present in mitral area, were compared with Doppler echocardiographic parameters suggestive of PH. Sensitivity (S), specificity (Sp) and positive (LR+) and negative (LR-) likelihood ratios were evaluated.

**RESULTS:** There was no significant correlation between  $S_2$  or  $P_2$  amplitude and PASP (pulmonary artery systolic pressure) ( $P = 0.185$  and  $0.115$ ;  $P = 0.13$  and  $0.34$ , respectively). Higher  $S_2$  in pulmonary area than in aortic area, compared with all the criteria suggestive of PH, showed  $S = 60\%$ ,  $Sp = 22\%$ ;  $LR+ = 0.7$ ;  $LR- = 1.7$ ; while  $P_2 > A_2$  showed  $S = 57\%$ ,  $Sp = 39\%$ ;  $LR+ = 0.9$ ;  $LR- = 1.1$ ; and  $P_2$  in mitral area showed:  $S = 68\%$ ,  $Sp = 41\%$ ;  $LR+ = 1.1$ ;  $LR- = 0.7$ . All these signals together showed:  $S = 50\%$ ,  $Sp = 56\%$ .

**CONCLUSIONS:** The semiological signs indicative of PH presented low sensitivity and specificity levels for clinically diagnosing this comorbidity.

## RESUMO

**CONTEXTO E OBJETIVO:** Hiperfonese de  $P_2$  tem sido considerada como achado valioso no diagnóstico semiológico de hipertensão pulmonar (HP). O objetivo foi de avaliar a acurácia do componente pulmonar da segunda bulha cardíaca em prever HP nos pacientes portadores de doenças intersticiais pulmonares. **TIPO DE ESTUDO E LOCAL:** Estudo transversal na Universidade de Brasília e Hospital de Base do Distrito Federal.

**MÉTODOS:** Os sons cardíacos foram adquiridos com estetoscópio eletrônico e analisados por fonocardiografia. Os sinais clínicos sugestivos de HP, como  $B_2$  mais intensamente audível em área pulmonar que aórtica,  $P_2 > A_2$  na área pulmonar e  $P_2$  presente em área mitral foram confrontados com parâmetros cardiográficos no exame de Doppler sugestivos de HP. Sensibilidade (S), especificidade (E), razões de verossimilhança positiva (RV+) e negativa (RV-) foram avaliados.

**RESULTADOS:** Não houve correlação significativa entre amplitude de  $B_2$  e  $P_2$  e a PSAP (pressão sistólica arterial pulmonar) ( $P = 0,185$  e  $0,115$ ;  $P = 0,13$  e  $0,34$ ; respectivamente). A análise da presença de  $B_2$  mais intensa na área pulmonar que aórtica, quando comparada a todos os critérios sugestivos de HP, mostrou  $S = 60\%$ ;  $E = 22\%$ ;  $RV+ = 0,7$ ;  $RV- = 1,7$ ; enquanto  $P_2 > A_2$  mostrou:  $S = 57\%$ ;  $E = 39\%$ ;  $RV+ = 0,9$ ;  $RV- = 1,1$ ; e  $P_2$  no foco mitral mostrou:  $S = 68\%$ ;  $E = 41\%$ ;  $RV+ = 1,1$ ;  $RV- = 0,7$ . Todos os sinais juntos mostraram  $S = 50\%$ ;  $E = 56\%$ .

**CONCLUSÃO:** Os sinais semiológicos indicativos de HP apresentam baixos valores de especificidade e sensibilidade para diagnóstico clínico dessa comorbidade.

## INTRODUCTION

Interstitial lung diseases are a heterogeneous group of disorders that affect the lung parenchyma. However, despite their differences, they all share chronic evolution associated with functional and structural deterioration of the pulmonary parenchyma.<sup>1</sup> This process is often also accompanied by pulmonary hypertension (PH), caused either by hypoxic pulmonary vasoconstriction or direct vascular impairment of vascular function, such as occurs in sarcoidosis.<sup>2</sup> The presence of PH is a predictor of mortality.<sup>3</sup>

Detecting the presence of PH is important because this disorder is a determining factor for various therapeutic measures, among them lung transplantation.<sup>3</sup> Moreover, a finding of PH may signal inapparent hypoxemia, such as occurs repeatedly during sleep or upon physical effort. Therefore, prompt and easy identification of factors that can provide additional information about the evolution of the disease is extremely important. In 1970, Harris<sup>4</sup> considered that both the intensity of the second heart sound ( $S_2$ ) and its behavior during breathing deserved attention during routine auscultation. A change in its characteristics could be an early clinical sign of PH.<sup>5</sup>

In this scenario, splitting of  $S_2$  mainly occurs because of delays in the pulmonary component ( $P_2$ ), although there is a slight advance of the aortic component ( $A_2$ ). This occurs even during expiration, with a delay of 0.02 to 0.03 seconds, and 0.02 in only 2% of the population, especially in children and young adults.<sup>6</sup>

Hyperphoresis of  $P_2$  has traditionally been acknowledged in all semiology books as indicative of PH. However, there is little evidence to support this. It is defined as more accentuated presence of  $S_2$  in the pulmonic area than in the aortic area<sup>5</sup> or, more specifically, as  $P_2 > A_2$  in the pulmonic area. It shows highly variable sensitivity (S) (96% to 58%) and specificity (Sp) (46% to 19%).<sup>5,7</sup>

In fact, it is not uncommon for a semiological tradition to be established based on pathophysiological deductions, without proper clinical validation of the finding, including its perceived variability, which has a direct relationship with the credibility and routine application of this knowledge on a daily basis. For instance, the reliability of cardiac auscultation findings is rarely evaluated. Regardless of these issues, hyperphoresis of  $P_2$  is still included in the guidelines for PH as an indicator of this condition.<sup>8</sup>

If, on the one hand, the benefits arising from a useful clinical finding, as a means for diagnosis that is doubly accessible in terms of both cost and speed of recognition, are enormous; on the other hand, acceptance of unproven validity can be harmful to the same extent. Therefore, it is increasingly important to determine the accuracy and real reliability of these clinical findings.

## OBJECTIVE

In this study, we aimed to evaluate the pulmonary component of  $S_2$  as a predictor of PH in patients with interstitial lung diseases. We also attempt to determine the pulmonary artery systolic pressure (PASP) value at which the pulmonary component of  $S_2$  would be a more useful predictor of PH.

## METHODS

This was a cross-sectional study from March to November 2011, in which 69 patients with various interstitial lung diseases seen in the outpatient care of a tertiary-level hospital were consecutively examined. This number was defined *a priori*, assuming an effect size of 0.4 *w* for the outcome, which represents a moderate to great effect, in addition to 80% power and an  $\alpha$  value of 5%.<sup>9</sup> The study protocol was approved by our institution's ethics committee and all the participating subjects signed an informed consent form.

Each participating patient underwent cardiac auscultation in a quiet environment, in the supine position, with spontaneous breathing. The sounds were recorded using a 3MM Littmann electronic stethoscope, model 3200 (St. Paul, MN, USA) for further analysis. Next, the patient underwent color Doppler echocardiography carried out by a single examiner who was unaware of any of the clinical data. Electrocardiographic monitoring was done during the test.

We evaluated 69 patients aged between 21 and 86 years, with a mean age of  $58 \pm 16.6$  years. Twenty-eight subjects (40.6%) were male and 41 (59.4%), female. Regarding the distribution of diseases, 15 patients (21.7%) had idiopathic pulmonary fibrosis, 22 (32%) had idiopathic interstitial diseases, 11 (16%) had interstitial lung disease associated with collagen-vascular disease, nine (13%) had sarcoidosis, seven (10.1%) had chronic hypersensitivity pneumonia and five (7.2%) presented other diffuse interstitial lung diseases.

## Phonocardiogram

Phonocardiograms corresponding to heart sounds obtained by means of an electronic stethoscope were recorded in the aortic, pulmonic, mitral and tricuspid areas. The recording was done during spontaneous and continuous breathing.

The pulse tracings were transformed into signals by means of the Zargis Cardioscan heart sound analysis software (Princeton, NJ, USA) and were adjusted for reading in accordance with the same measurement scale. The amplitude of  $S_2$  was measured (with or without splitting) and the amplitude of its  $P_2$  component was measured separately; both measurements were obtained in the pulmonic area.

The parameters subsequently evaluated were the relative intensities of  $A_2$  and  $P_2$  in the pulmonic area; occurrences of

$P_2$  of greater amplitude than  $A_2$  ( $P_2 > A_2$ );  $P_2$  in the mitral area; absence of splitting of  $S_2$ ; and, finally, simultaneous occurrence of all the parameters.

The analyses were performed by three independent examiners. They took into consideration the sounds, the pulse tracings and the additional features of the software, which made it possible to view the spectrums of the phonographic wave forms, among other things. Decisions were then based on the consensus reached among the examiners.

Phonocardiogram results were also compared with PASP measurements by means of Doppler echocardiography, using Doppler and additional criteria for diagnosing PH, as described below.

### Transthoracic Doppler echocardiography

For transthoracic Doppler echocardiography evaluations, the patients were examined in the left lateral decubitus position, using standard echocardiographic projections. We used an ultrasound machine (model Vivid S5, General Electric, Milwaukee, WI, USA) with a multifrequency transducer and a frequency range from 2.5 to 3.5 MHz.

Measurements of variables relating to the heart chambers and ventricular function were obtained as established by the American Society of Echocardiography.<sup>10</sup>

Doppler analyses were performed in real time. Doppler color flow mapping in multiple views was used in order to more accurately measure tricuspid regurgitation. We used continuous wave Doppler ultrasound at a sweep speed of 50-100 mm/sec. Three to five measurements per pulse tracing were taken.

To calculate PASP by measuring tricuspid regurgitation, we used the modified Bernoulli equation. We then obtained the pressure gradient between the right ventricle (RV) and right atrium (RA). The estimated right atrial pressure was added to this parameter,<sup>11,12</sup> given that there was no right ventricular outflow tract obstruction.

Right atrial pressure was obtained by assessing the percentage collapse and the diameter of the inferior vena cava during spontaneous breathing. If the inspiratory collapse was greater than 50% and the diameter was less than 2.1 cm, the pressure added was 5 mmHg; if the inspiratory collapse was less than 50% and the diameter was greater than 2.1 cm, the pressure added was 10 mmHg; in patients where the inferior vena cava plethora was markedly greater than 2.1 cm and collapse was less than 50%, the pressure added was 20 mmHg.<sup>13-15</sup>

### Pulmonary hypertension criteria

Pulmonary hypertension was considered "probable" when PASP was greater than 50 mmHg.<sup>15,16</sup> It was considered "possible" when PASP fluctuated between 37 and 50 mmHg, or when it was below 37 mmHg and accompanied by additional echocardiographic

variables of PH, including the existence of dilation and/or hypertrophy of the right chambers, paradoxical movement of the interventricular septum or right ventricular dysfunction (analyzed in accordance with the recommendations of the American Society of Echocardiography for evaluating the right chambers).<sup>15</sup>

### Data analysis

Continuous variables were described as the mean plus or minus standard deviation, along with the amplitude. Categorical variables were expressed as percentages. We conducted analyses on the correlations of the amplitudes of  $S_2$  and  $P_2$  in relation to PASP with the aim of assessing the influence of one variable on another. Since these variables did not show normal distribution according to the Shapiro-Wilk test, the Spearman correlation coefficient was used.

A receiver operating characteristic (ROC) curve with its components of sensitivity (S), specificity (Sp) and positive (LR+) and negative (LR-) likelihood ratios was constructed in order to determine the discriminatory power of each parameter studied. The area under the curve was expressed in terms of the 95% confidence interval (95% CI).

The findings were considered statistically significant when the probability P for two-tailed tests was  $P < 0.05$ . The data were analyzed using the Statistical Package for the Social Sciences (SPSS) software version 20 and Excel, both for the Mac OS X operating system.

### RESULTS

The prevalence of PH in the sample, when all the echocardiographic criteria were taken into consideration, was 73% in patients with idiopathic pulmonary fibrosis, 41% in those with idiopathic diseases, 27% in those with collagen-vascular disease, 22% in those with sarcoidosis, 25% in those with chronic hypersensitivity pneumonia and 25% in those with other diffuse lung diseases. In these patients, the forced vital capacity (FVC) showed a mean of  $67 \pm 22.7\%$ , with a minimum value of 18% and maximum of 110%. Hemoglobin oxygen saturation ( $SpO_2$ ) in ambient air showed a mean of  $93.4 \pm 4.8\%$  and a minimum value of 70% and maximum of 99%.

PASP estimated by means of Doppler echocardiography (which was feasible in all tests) was normal in 41 patients (59.4%), while 17 (24.7%) had additional echocardiographic criteria that, together with PASP, were suggestive of PH (possible PH). In 11 patients (15.9%), the PASP values measured by means of Doppler indicated PH (probable PH). Therefore, the combination of all the criteria measured through the examination led us to observe PH in 28 patients (40.6%).

**Table 1** shows the frequencies of the clinical findings studied. For each analysis of S and Sp, we observed low values for

all phonocardiographic parameters, in comparison with Doppler echocardiographic criteria, as shown in Tables 2 and 3.

From observing the behavior of the maximum amplitude of  $S_2$  on phonocardiography (with or without splitting) and the amplitude of  $P_2$ , in relation to the variation of PASP, we obtained a weak and not statistically significant correlation. The correlation index  $\rho$  was 0.185 for  $S_2$  ( $P = 0.13$ ) and 0.115 for  $P_2$  ( $P = 0.34$ ).

In assessing the ROC curve, the best cutoff point for PASP was defined as 53 mmHg. At this pressure, simultaneous presence of the three clinical signs studied showed  $LR+ = 2.32$  and  $LR- = 0.88$ . The area under the curve was 0.518 (95% CI: 0.376 to 0.659;  $P = 0.80$ ). This value was very close to the limit set for probable PH. Considering the pretest probability to be the prevalence of PH above 53 mmHg within the sample studied (which was 13%), the post-test probability would increase to 26%. For each clinical sign isolated, there were no points on the curve that yielded  $LR+$  greater than 2 or  $LR-$  less than 0.5.

**Table 1.** Frequencies of clinical findings surveyed

Phonocardiography	Sign present n = 69	Sign absent n = 69
$S_2$ more intense in the pulmonic area than in the aortic area	49 (71.0%)	20 (29.0%)
$P_2 > A_2$	41 (59.4%)	28 (40.6%)*
$P_2$ in the mitral area	43 (62.3%)	26 (37.7%)
All signs present simultaneously	32 (46.4%)	37 (53.6%)

\*Splitting was not observed in 9 patients (13%).

**Table 2.** Comparison between clinical findings predictive of pulmonary hypertension (probable)

	S	Sp	LR+	LR-	P
$S_2$ more intense in the pulmonic area than in the aortic area	63%	27%	0.9	1.3	0.50
$P_2 > A_2$	63%	41%	1.0	0.9	0.90
$P_2$ in the mitral area	63%	37%	1.0	0.9	0.90
All signs present simultaneously	63%	57%	1.4	0.6	0.20

S = sensitivity; Sp = specificity; LR+ = positive likelihood ratio; and LR- = negative likelihood ratio.

**Table 3.** Comparison between clinical findings predictive of pulmonary hypertension (possible and probable)

	S	Sp	LR+	LR-	P
$S_2$ more intense in the pulmonic area than in the aortic area	60%	22%	0.7	1.7	0.12
$P_2 > A_2$	57%	39%	0.9	1.1	0.70
$P_2$ in the mitral area	68%	41%	1.1	0.7	0.40
All signs present simultaneously	50%	56%	1.1	0.9	0.60

S = sensitivity; Sp = specificity; LR+ = positive likelihood ratio; and LR- = negative likelihood ratio.

## DISCUSSION

This study included patients with several types of interstitial lung diseases, with different FVC values and degrees of hypoxemia at the time of evaluation. We observed a range of situations: normal PASP values, mild degrees of PH and also markedly elevated levels of the disease, which constituted the later stages of this comorbidity.

The prevalence of PH in these diseases varies widely according to the diagnosis and pulmonary involvement. It is also a predictor of morbidity and mortality.<sup>17-19</sup>

Doppler echocardiography has been used in other clinical studies to trace PH, in which the prevalence of this disorder was between 5.7% and 73.8% when pulmonary involvement was due to sarcoidosis.<sup>20</sup> In interstitial diseases relating to collagenosis, especially scleroderma, the prevalence of PH was around 18.1%.<sup>21</sup> In idiopathic pulmonary fibrosis, these data are not yet well defined, with the possibility of reaching 84% in patients with advanced degrees of pulmonary involvement.<sup>22</sup> Other authors have also demonstrated its occurrence in one third of patients with IPF (interstitial pulmonary fibrosis).<sup>23</sup> In the present study, the prevalence rates of PH were in agreement with the range of values previously reported.

Since the recognition of inspiratory splitting of the second heart sound by Potain<sup>24</sup> 100 years ago, numerous studies have tried to explain how these heart sound variations occur and whether these changes can be attributed to various disorders. Analyses have been conducted with the aim of comparing traditional phonocardiograms with intracardiac pressure measurements made through cardiac catheterization, in order to relate pressure values to semiological findings.

There are no studies comparing intracardiac pressure measurements obtained using Doppler echocardiography with digital phonocardiogram pulse tracings obtained using an electronic stethoscope, in which patients with interstitial lung disease were specifically targeted. However, the reasons that would lead to increased PASP and possible semiological changes would be similar to those found in other diseases.

The relative intensities of heart sounds are still an integral part of auscultation. In cases of PH, the explanation for findings that the pulmonary component of the second heart sound presents greater intensity than that of the aortic component is believed to be associated with hemodynamic concepts and factors relating to the anatomy of the pulmonary artery.<sup>25</sup> However, there is still controversy about the exact mechanism of this phenomenon.

Earlier studies<sup>25-27</sup> indicated that the amplitude of the  $P_2$  component in PH may not differ significantly from that of  $A_2$ . This would be explained by the fact that although the diastolic pressure gradient in the right ventricle is elevated in this condition, it would not exceed the gradient of the left chamber. In this regard, increased amplitude of the  $P_2$  component could only be

expected in those few patients with PH in the later stages of the disease, in which the rate of increase of this gradient would be extremely high. Nevertheless, the analysis on this component did not show statistical significance.<sup>25</sup>

One anatomical factor that could also contribute towards greater amplitude of  $P_2$  in cases of PH would be greater surface area of the pulmonary valve and higher pulmonary artery distensibility, which would produce intense vibration of the semilunar valves, in comparison with the aortic valve. The combination of these factors was significant.<sup>26,27</sup> The data from our study were consistent with the facts previously described and also showed no relationship between higher amplitude of the  $P_2$  component measured by means of phonocardiography and elevated PASP levels measured by Doppler echocardiography.

The PASP values estimated by means of color Doppler echocardiography showed a good correlation with invasive measurements ( $r = 0.92$ ). The S and Sp values for predicting PH ranged from 79 to 100% for S and from 60 to 98% for Sp, in a study showing high prevalence of PH.<sup>28</sup>

Through evaluating the presence of clinical findings suggestive of PH and comparing the data with measurements of PASP by means of Doppler echocardiography, we noted that our values for S and Sp and the ratios for LR+ and LR- were of low clinical relevance, even when the pulmonary pressure levels were high. The findings from clinical studies that did not report any relationship between the relative intensities of the components of  $S_2$  found through phonocardiography and measurements of pulmonary pressure through catheterization<sup>29</sup> are in agreement with these data. Other clinical findings such as  $P_2$  with higher amplitude than  $A_2$  and the presence of  $P_2$  in the mitral area were also compared in other studies in which pressure measurements were made by means of catheterization. There was no relationship between elevated measurements and the existence of these signs. In this context, the S and Sp values for high-amplitude  $P_2$  components were respectively 58-96% and 19-46%, thus demonstrating a wide variation.<sup>5,7</sup>

So far, the results from rigorous analysis on the S and Sp of semiological findings predictive of PH that were associated with the second heart sound have not been conclusive. However, our results showed that the discriminatory power of each of the clinical parameters evaluated was not very important for the diagnostic suspicion of PH "at the bedside".

It should be noted that even the data from the NIH registry, which was a relevant prospective study, refer to the existence of an accentuated pulmonary component of the second heart sound, seen on clinical examination in more than 90% of the patients with PH, irrespective of its cause.<sup>30</sup> However, the NIH study aimed to investigate factors associated with survival in this population. The only concern was to report the clinical findings, without determining the S and Sp of these semiological findings.

Thus, considering a context in which the prevalence of PH is high, findings of physical signs with high Sp would increase the likelihood of the disease post-test. Absence of signs showing high S would practically dismiss this possibility, and this would be useful for tracing. Our data demonstrated that these signs do not have the capacity to confirm the presence or absence of the disease. Other methods such as Doppler echocardiography are required in order to diagnose this complication.

## CONCLUSIONS

Therefore, we can conclude that, in the context of symptomatic evaluation for predicting PH in patients with interstitial diseases, clinical signs are not useful. Their pathophysiological concepts would only be useful for academic thinking. These signs cannot take on the function of reaching a diagnosis.

## REFERENCES

1. Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. *Mayo Clin Proc.* 2007;82(8):976-86.
2. Leslie KO. Pathology of interstitial lung disease. *Clin Chest Med.* 2004;25(4):657-703, vi.
3. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. *Eur Respir J.* 2008;31(6):1357-67.
4. Harris A. The second heart sound in health and in pulmonary hypertension. *Am Heart J.* 1970;79(2):145-8.
5. Fowler NO, Noble WJ, Giarratano SJ, Mannix EP. The clinical estimation of pulmonary hypertension accompanying mitral stenosis. *Am Heart J.* 1955;49(2):237-49.
6. Harris A, Sutton G. Second heart sound in normal subjects. *Br Heart J.* 1968;30(6):739-42.
7. Whitaker W. Clinical diagnosis of pulmonary hypertension in patients with mitral stenosis. *Quarterly Journal of Medicine.* 1954;23(89):105-12. Available from: <http://qjmed.oxfordjournals.org/content/23/1/105>. Accessed in 2015 (Sep 15).
8. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for diagnosis and treatment of pulmonary hypertension. *Eur Respir J.* 2009;34(6):1219-63.
9. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods.* 2007;39(2):175-91.
10. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr.* 2005;18(12):1440-63.

11. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. *J Am Coll Cardiol.* 1985;6(2):359-65.
12. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med.* 2009;179(7):615-21.
13. Ommen SR, Nishimura RA, Hurrell DG, Klarich KW. Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. *Mayo Clin Proc.* 2000;75(1):24-9.
14. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. *J Am Coll Cardiol.* 1985;6(4):750-6.
15. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr.* 2010;23(7):685-713; quiz 786-8.
16. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol.* 2004;43(12 Suppl S):5S-12S.
17. Olschewski H, Ghofrani HA, Walmrath D, et al. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis]. *Pneumologie.* 2000;54(3):133-42.
18. King TE Jr, Toozé JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. *Am J Respir Crit Care Med.* 2001;164(7):1171-81.
19. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). *Q J Med.* 1992;82(298):139-48.
20. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. *Chest.* 2006;129(5):1246-52.
21. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. *J Rheumatol.* 2003;30(11):2398-405.
22. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Chest.* 2005;128(4):2393-9.
23. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest.* 2006;129(3):746-52.
24. Potain C. Note sur les dédoublements normaux des bruits de coeur. *Bull Mem Soc Méd Hop Paris.* 1866;3:138.
25. Sabbah HN, Stein PD. Investigation of the theory and mechanism of the origin of the second heart sound. *Circ Res.* 1976;39(6):874-82.
26. Stein PD, Sabbah HN, Anbe DT, Khaja F. Hemodynamic and anatomic determinants of relative differences in amplitude of the aortic and pulmonary components of the second heart sound. *Am J Cardiol.* 1978;42(4):539-44.
27. Kusakawa R, Bruce DW, Sakamoto T, Mac Canon DM, Luisada AA. Hemodynamic determinants of the amplitude of the second heart sound. *J Appl Physiol.* 1966;21(3):938-46.
28. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest.* 2004;126(1 Suppl):14S-34S.
29. Sutton G, Harris A, Leatham A. Second heart sound in pulmonary hypertension. *Br Heart J.* 1968;30(6):743-56.
30. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med.* 1991;115(5):343-9.

**Sources of funding:** None

**Conflict of interest:** None

**Date of first submission:** April 12, 2015

**Last received:** June 7, 2015

**Accepted:** July 12, 2015

**Address for correspondence:**

Sandra de Barros Cobra Negreiros

SQSW 305 — Bloco G — apto 609

Setor Sudoeste — Brasília (DF) — Brasil

CEP 70673-427

Cel. (+5561) 9972-1013

Tel. (+55 61)3361-7744

E-mail: sandrab.cobra@gmail.com